The Individual Coverage Health Reimbursement Arrangement (ICHRA) market has reached a tipping point. Enrollment nearly tripled in 2026—a 2.8x increase over 2025, with between 400,000 and 800,000 Americans now enrolled and the redistribution of group membership has begun. This is not incremental change.

Employer cost pressure, individual premium competitiveness, and growing legislative tailwinds are converging to accelerate adoption, and the window to build a credible market position narrows with each open enrollment cycle.

The Stakes

• Revenue Exposure: ~$140 PMPM gap for plans not positioned as the ICHRA landing carrier.
• Competitive Window: Closing with each enrollment cycle as platforms lock in carrier partnerships.
• Strategic Debt: Compounding with each renewal cycle without an ICHRA strategy widens the gap.

Yet not every health plan should enter the ICHRA market, and not every plan that enters will be competitive. The landscape is solidifying around a small number of aggressive movers. Centene's Marketplace membership grew 29% year-over-year in Q1 2025.^[1]  Oscar Health reported a 42% revenue increase in the same period, with membership approaching two million lives.^[1] The plans on the sidelines are accumulating strategic debt. For a plan with 100,000 small group lives, even a 10% migration represents $14 million in annual revenue exposure per 10,000 lives that leave for another plan.

Strategic debt accumulates each renewal cycle where employers migrate without a corresponding ICHRA strategy, compounding future membership loss and weakening broker and provider positioning. Plans that approach ICHRAs incrementally will underperform those with purpose-built capabilities. ICHRAs are a direct extension of the ACA individual market into employer-sponsored coverage, not a standalone product strategy.

The platform ecosystem is a critical and frequently underestimated competitive differentiator. Seven leading vendors now define distribution, steerage, and ultimately which carrier wins enrollment. The build vs. buy vs. partner decision has material implications for time-to-market, member data rights, and long-term economics.

The risks are real and frequently underpriced. Adverse selection, risk adjustment exposure, and ACA market instability require active modeling before launch, not reactive management after it. Treating risk management as a post-launch activity is not a recoverable mistake.

Health plan leadership must answer key questions addressing market size, product readiness, platform discipline, actuarial rigor, organizational alignment, and regulatory resilience. This is not a product decision, it is a portfolio decision. The degree to which leadership can address these with confidence and data will determine whether this is a durable growth strategy or a costly market experiment.

READ THE FULL PAPER

[1] Thatch. (2025, May). Why Oscar Health and Centene Are Investing in ICHRAs. https://thatch.com/blog/why-health-insurers-like-oscar-and-centene-are-investing-in-ichras